GlassScriptPhysician profile
Muhammad A Salamat
NPI 1467427740
$78,109.59
in general payments reported to CMS, 2019-2025
60 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $9,240 · 2021: $18K · 2022: $11K · 2023: $3,839 · 2024: $4,254 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,354 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,715 · Travel and Lodging: $812 · Consulting Fee: $400 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,353.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,715.00 |
| Travel and Lodging | $811.81 |
| Consulting Fee | $400.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19,701.33 | 2019-2025 | Calquence, Enhertu, Tagrisso |
| Genentech USA, INC. | $17,879.28 | 2019-2025 | Phesgo, Itovebi |
| Celgene Corporation | $7,363.39 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Cardinal Health 110 LLC | $7,250.00 | 2019-2023 | |
| Exelixis INC. | $5,790.14 | 2019-2024 | Cabometyx |
| Janssen Biotech, INC. | $3,503.71 | 2019-2025 | Rybrevant, Erleada, Akeega |
| Seagen INC. | $3,207.00 | 2019-2023 | Adcetris, Padcev |
| G1 Therapeutics, INC. | $3,000.00 | 2021-2022 | |
| Abbvie INC. | $2,194.91 | 2022-2025 | |
| Daiichi Sankyo INC. | $994.54 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Janssen Scientific Affairs, LLC | $757.50 | 2022 | |
| Pfizer INC. | $587.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $553.00 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $545.25 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $494.17 | 2019-2025 |
Show all 59 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Salamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.